| 產(chǎn)品名稱 | Vidofludimus - 4SC-101 | SC 12267 |
| 產(chǎn)品貨號 | Axon 2377 CAS [717824-30-1] MF C20H18FNO4MW 355.36 Purity: 99% Soluble in DMSO Description Oral immunomodulatory drug that inhibits dihydroorotate dehydrogenase (DHODH; IC50 value 134 nM for human DHODH mediated DCIP reduction) and lymphocyte proliferation in vitro. Vidofludimus inhibits the proliferation of human peripheral blood mononuclear cells (PBMCs) stimulated with Phytohemagglutinin-L, and interleukin (IL)-17 secretion from human peripheral blood mononuclear cells in a dose-related fashion (IC50 of 6 μM approx.) and independently of lymphocyte proliferation. May be applied for treatment of rheumatoid arthritis and inflammatory bowel disease, and as immunosuppressant after renal transplantation. References Certificates Categories Extra info J. Leban et al. SAR, species specificity, and cellular activity of cyclopentene dicarboxylic acid amides as DHODH inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 4854-4857. ? K. Rusai et al. Immunosuppression with 4SC-101, a novel inhibitor of dihydroorotate dehydrogenase, in a rat model of renal transplantation. Transplantation. 2012, 93, 1101-1107. ? L.R. Fitzpatrick et al. Vidofludimus inhibits colonic interleukin-17 and improves hapten-induced colitis in rats by a unique dual mode of action. J. Pharmacol. Exp. Ther. 2012, 342, 850-860. ? L.R. Fitzpatrick et al. Inhibition of IL-17 as a pharmacological approach for IBD. Int. Rev. Immunol. 2013, 32, 544-555. Certificate of Analysis Material Safety Data Sheet Immunology Pain & Inflammation Immunomodulator DHODH EC 1.3.3.1 Oral immunomodulatory drug that inhibits dihydroorotate dehydrogenase (DHODH) Chemical name 2-(3-fluoro-3'-methoxybiphenyl-4-ylcarbamoyl)cyclopent-1-enecarboxylic acid Parent CAS No. [717824-30-1] Order Size Unit Price Stock 5 mg €125.00 In Stock |
| 產(chǎn)品價格 | 現(xiàn)貨詢價，電話：010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
Vidofludimus - 4SC-101 | SC 12267Axon 2377 CAS [717824-30-1] MF C20H18FNO4
Description
Oral immunomodulatory drug that inhibits dihydroorotate dehydrogenase (DHODH; IC50 value 134 nM for human DHODH mediated DCIP reduction) and lymphocyte proliferation in vitro. Vidofludimus inhibits the proliferation of human peripheral blood mononuclear cells (PBMCs) stimulated with Phytohemagglutinin-L, and interleukin (IL)-17 secretion from human peripheral blood mononuclear cells in a dose-related fashion (IC50 of 6 μM approx.) and independently of lymphocyte proliferation. May be applied for treatment of rheumatoid arthritis and inflammatory bowel disease, and as immunosuppressant after renal transplantation.
Oral immunomodulatory drug that inhibits dihydroorotate dehydrogenase (DHODH)
Chemical name2-(3-fluoro-3'-methoxybiphenyl-4-ylcarbamoyl)cyclopent-1-enecarboxylic acid Parent CAS No.[717824-30-1] |
| 產(chǎn)品資料 |
